Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.542 -0.088 (-1.15%)
Streaming Delayed Price Updated: 12:28 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
Via Investor Brand Network
Topics Intellectual Property
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics... 
Via Benzinga
Topics Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
Via Investor Brand Network
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
Via Investor Brand Network
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones
Via Investor Brand Network
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
Via Investor Brand Network
Cybin to Participate at the 27th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”
Via Investor Brand Network
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
Via Investor Brand Network
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
Via Investor Brand Network
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.